Get started
Cara Therapeutics, Inc.Cara Therapeutics, Inc.Cara Therapeutics, Inc.

Cara Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Seasonals

CARA chart


Full chart

CARA upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪18.64 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.0385 USD
Net income (FY)
‪−118.51 M‬ USD
Revenue (FY)
‪20.97 M‬ USD
Shares float
‪45.76 M‬
Beta (1Y)
1.07

Employees


Employees (FY)
55
Change (1Y)
−51 −48.11%
Revenue / Employee (1Y)
‪381.24 K‬ USD
Net income / Employee (1Y)
‪−2.15 M‬ USD

About Cara Therapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Christopher A. Posner
Website
caratherapeutics.com
Headquarters
Stamford
Founded
2004
FIGI
BBG001J2QYS9
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

CARA news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of CARA is 0.3399 USD — it has decreased by −1.48% in the past 24 hours. Watch Cara Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Cara Therapeutics, Inc. stocks are traded under the ticker CARA.
CARA stock has risen by 9.65% compared to the previous week, the month change is a 35.96% rise, over the last year Cara Therapeutics, Inc. has showed a −72.37% decrease.
CARA reached its all-time high on Apr 9, 2021 with the price of 29.6473 USD, and its all-time low was 0.2400 USD and was reached on Jun 17, 2024. View more price dynamics on CARA chart.
See other stocks reaching their highest and lowest prices.
CARA stock is 13.35% volatile and has beta coefficient of 1.07. Track Cara Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Cara Therapeutics, Inc. there?
Today Cara Therapeutics, Inc. has the market capitalization of ‪18.64 M‬, it has increased by 13.65% over the last week.
Yes, you can track Cara Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Cara Therapeutics, Inc. is going to release the next earnings report on Nov 11, 2024. Keep track of upcoming events with our Earnings Calendar.
CARA earnings for the last quarter are −0.27 USD per share, whereas the estimation was −0.27 USD resulting in a 1.46% surprise. The estimated earnings for the next quarter are −0.24 USD per share. See more details about Cara Therapeutics, Inc. earnings.
Cara Therapeutics, Inc. revenue for the last quarter amounts to ‪1.10 M‬ USD, despite the estimated figure of ‪1.18 M‬ USD. In the next quarter, revenue is expected to reach ‪2.02 M‬ USD.
CARA net income for the last quarter is ‪−20.02 M‬ USD, while the quarter before that showed ‪−30.70 M‬ USD of net income which accounts for 34.79% change. Track more Cara Therapeutics, Inc. financial stats to get the full picture.
No, CARA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 10, 2024, the company has 55.00 employees. See our rating of the largest employees — is Cara Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Cara Therapeutics, Inc. EBITDA is ‪−104.26 M‬ USD, and current EBITDA margin is −578.20%. See more stats in Cara Therapeutics, Inc. financial statements.
Like other stocks, CARA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Cara Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Cara Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Cara Therapeutics, Inc. stock shows the sell signal. See more of Cara Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.